• Hi there! This is Polly Peng, I’m currently a sophomore at Boston University studying Data Science. I have a lot of interests including watching films, photography, traveling and communicating with different people. I just love discovering new things! Joining Health Earth Association has been a pleasure for me; I gain so much positive energy from the people working or supervising here. Most importantly, to have the same purpose as our non-profit, - to benefit others as much as possible with health information has always been empowering to me!
• 大家好！我是Polly Peng，目前就读于波士顿大学读大二。主修大数据专业。我喜欢看电影，摄影，旅游，和不同的人交流等等。喜欢发现新事物，很高心能够加入新方舟这个充满正能量的大家庭，在这里也希望可以尽自己的一份力量利益到更多的人！

• 中医名专家、针灸专家
• 非遗“独龙针”第26代唯一传人
• 非遗“龙门正骨”第26代唯一传人
• 佛山职业技术学院客座教授
• 顺德职业技术学院客座教授
• 广州卫生职业技术学院客座教授
• 中国中医药研究促进会中医药传承发展工作委员会会员
• 北京青爱教育基金会健康与文化教育专业委员会委员
• “俞梦孙院士人民健康系统工作委员会”常委理事
• 德耆慈善基金会罗俊卿康养专项基金暨善耆家园医学顾问
• 出身于中医世家，曾受北京中医界有名的双桥老太太罗有明熏陶指点学习中医；遍访名师，研习各家医术。也是中国工程院俞梦孙院士的弟子，并师从北京白云观掌教曹信义道长学习道医“龙门医学”。在骨伤治疗手法、针灸、中医研究等方面具有独到的造诣，多次为国内有关政要人员诊疗保健。
• 擅长运用道医“独龙针”及龙门丹药医治疑难杂症和绝症；对骨伤治疗手法、针灸、方药和药食同源方面有独门疗法。
• 曾受邀到多个国家及地区从事中医教学、推广和义诊等，扩大了中医在国际上的影响力，在国际中医界内享有良好的口碑。

• Dr. Guanhu Yang graduated from Zhejiang College of Traditional Chinese Medicine (MD) and Nanjing College of Traditional Chinese Medicine (MS), and served as Assistant Professor at Wenzhou Medical University. In 1993, Guanhu joined the staff of Toyama Medical and Pharmaceutical University in Japan, and from there he went to Kanazawa Medical University for his Ph.D. study in lung repair. After completion of his Ph.D., Dr. Yang continued his research in pulmonary biology at Cincinnati Children's Hospital as a postdoc and then research scientist.
• Dr. Yang has been running two acupuncture clinics in Ohio, USA. He is currently a Clinical Professor at Ohio University, and Chair Professor of the US-China Joint Institute for Acupuncture & Rehabilitation Medicine at Wenzhou Medical University. Dr. Yang also have served as director for the SHI acupuncture school, vice president at American TCM Association few years ago, and supervised the doctoral program at American Academy of Acupuncture & Oriental Medicine and other 10 medical university in the World. He is president of Chinese Medicine Luobing Society of American. During his career, Dr. Yang published 11 books and over 80 research articles on basic biology and traditional Chinese medicine, and work as editor and reviewer for numerous renowned SCI journals. Dr. Yang also is associate Editor for International Journal of Clinical Acupuncture. He also is Vice president of the World Federation of Chinese Medicine digestion Committee and Endocrine Committee.
•  杨观虎教授 ,1985年毕业于浙江中医学院，同年进入南京中医学院攻读温病学研究生。1987年到1993 年在温州医学院附属二院中医科担任讲师，1993年考取笹川医学奖学金，由卫生部派往日本富山医科薬科大学第一内科从事糖尿病的研究，二年后转入金沢医科大学研究生院呼吸内科并获医学博士。
• 1999年来美国于辛辛那提儿童医疗中心从事呼吸生理学的博士后研究。2005-2009年担任俄亥俄州SHI针灸学校校长。现为北京中医药大学、温州医科大学、浙江中医药大学和南京中医药大学客座教授，俄亥俄大学医学院临床教授，温州医科大学中美联合针灸康复研究所美方所长，美国加州五系中医药大学，德州华美中医学院、佛州大西洋中医学院，明州美国中医学院及英国的南京/英国淑兰中医学院博士班导师，美国络病学会会长，美国中药学会副会长，纽约执照针灸师公会顾问，并担任世界中医联合会（世中联）监事会执行委员，世中联糖尿病诊治标准制定组成员，世中职内科委常务理事；世中联古典名方研究会副会长，世中联消化委员会副会长，世中联内分泌委员会副会长，世中联方药量效研究会副会长及世中联态靶辨治专委会副会长等职务。2016年到2018年曾任全美中医药学会副会长。
• 在美国有俄亥俄州、纽约州、马里兰州和弗吉尼亚州的中医针灸执照，拥有两个中医诊所，担任Pharmacological Research 等多家SCI杂志特约审稿专家，《中国针灸》杂志编委，《International Journal of Clinical Acupuncture》副主编，《Frontiers of Neuroscience》专刊客座主编。 多次受邀在哈佛中医讲坛等著名大学及学会作演讲，参与主编和编译了11本中医和现代医学著作，并发表SCI为主的论文80多篇。

• With over 20 years of experience in cancer research and drug development, Dr. Yilong Zhang has experience working in Allergan, Novartis, Amgen, and Esperion with increasing roles and responsibilities in Research and Development of Pharmaceutical Industry.
•  Dr. Zhang obtained Bachelor and Master Degrees in Medicine from Beijing Medical University in 1990s and PhD Degree in Pharmaceutical science from The Ohio State University in early 2000s. Recently, he obtained a Master Degree in Acupuncture from Alhambra Medical University. 
• Currently, Dr. Zhang is serving as the Vice President of Clinical Development at Fulgent Pharma LLC. His work is focusing on discovering and developing of novel therapeutic agents for unmet medical needs.

孙志涛，博士，博士后，美国访问学者，深圳市中医院骨科副主任医师

教育经历

(1) 2010-9至2013-6, 广州中医药大学, 博士研究生

(2) 2007-9至2010-6, 安徽中医学院, 硕士，硕士研究生

工作经历

(1) 2018-6至2021-12, 上海中医药大学, 博士后

(2) 2018-7至2019-7, 美国南加州大学凯克医学院，访问学者

(3) 2013-8至现在, 深圳市中医院，副主任医师

(4) 2003-11至2007-3, 安徽中医学院附属中西医结合医院，住院医师

学会任职

• 中国医师协会会员
• 中华中医药学会精准医学第二届委员会青年委员
• 第五届中国老年学和老年医学学会老年病学分会委员
• 中国中西医结合学会骨伤科分会第八届委员会椎间盘退变与修复专家委员会委员
• 国际矫形与创伤外科学会之Sicot中国部数字骨科学会广东省分会青年委员
• 广东省医疗行业协会中医中药管理分会深圳市医学会骨科专业委员会脊柱微创学组委员
• 广东省中西医结合学会委员
• 深圳市中医骨伤科委员会委员
• 深圳市中西医结合学会神经外科专业委员会第一届委员
• 深圳市健康管理协会脊柱脊髓专业委员会委员
• 深圳市中医药学会肿瘤诊疗与康复专业委员会委员
• 学术奖励情况
• 获2017年度广州中医药大学临床教学查房比赛二等奖
• 获2018年深圳市住院医师规范化培训优秀带教老师
• 获2019年度第36届国际医疗品质协会优秀组织奖
• 获2014-2015、2016-2017、2017-2018、2018-2019年度“优秀教师”称号
• 参加中华医学会第十九届骨科学术会议暨第十二届COA国际学术大会，获证书
• 主持和参与国家级、省级、市级课题9项，发表论文40余篇。擅长治疗膝骨关节炎，无菌性股骨头坏死，肩周炎，腰椎间盘突出症，腰椎椎管狭窄症等骨科疾病。

HIGHLIGHTS

•  Strong executive background with over 10 years of experience in setting up companies and running businesses
• Strong management skills with 7 years of experience as a medical research project manager
•  Familiarity with GCP and ICH guidelines, including a basic understanding of regulatory requirements
•  Familiarity with clinical trial process with 5+ years of experience in clinical research and 10+ years of experience in medical research.
• Strong data analysis skills.
• Excellent organization, planning and problem solving abilities. 
• Excellent negotiation and analytical skills. 

EDUCATION 

• B. S. Biochemistry, Jilin University, Changchun, P.R. China, 1984 
• Ph. D. Biomedical, Dalian Medical University, Dalian, P.R. China, 1996 

LICENSURE

• CLSp (MB) Certified Clinical laboratory specialist in molecular biology,NCA, USA. 2003

TRAINING

•  Postdoctoral, Clinical Pathology Lab, Research Institute, 03/96-03/98

William Beaumont Hospital, MI 48073

WORK AND MANAGEMENT EXPERIENCES

President

Yurise Foundation, Houston, TX 77036（09/22-Current）

•  Serves as the organization’s primary spokesperson by leading key public engagements, and nurturing relationships within the community.
• Works closely with the Yurise board to develop strategy, identify opportunities, address issues, and develop recommendations to further the organization’s impact.
• Oversees communication with internal/external stakeholders, ensuring messaging amplifies the organization’s mission, programs, and impact in accordance with the organization’s values
• Exhibits sound fiscal budget management, with maximum resource utilization and maintenance of the organization’s positive financial position.
• Dedicates significant attention to fundraising initiatives and activities in partnership with the Fund Development team.
• Demonstrate cultural awareness and actively foster an inclusive, culturally sensitive environment. Willingness to ask questions, learn, and constructively share and accept feedback.
• Develops a diverse team of staff and volunteers who reflect the community they serve, and support the organization’s mission, goals, and core values.

Chief Executive Officer （CEO）

CHM BioHealth LLC, Austin, TX 78750 9/13-Current）

• Establishing overall direction and strategic initiatives for the given major function or line of business
• Establishing financial goals and profitability
• Developing Bio Health Programs and operational standards
• Directs and coordinates the business operation
• Report to a board of directors
• Managing a business unit, division or corporate function with major organizational impact 

Chief Operation Officer （COO）

CHM Adult Care Center, Austin, TX 78681(06/13-11/18)

• Participate in application for a license from Texas Department of Aging and Disability Services
• Consultation of medical knowledge

Clinical Trial Principle Investigator 

Karmanos Cancer Institute, National Center of Vermiculite and Asbestos (NCVAC) Wayne State University, Detroit, MI 48201 (04/08-09/13)

Biomarker trial for the diagnosis of mesothelioma with experiences in:

• Hiring and training research associates and assistants
•  Designing and planning the research project
• IRB application
• Writing and modification of protocols
• Development of informed  consent documents
• Recruitment and enrollment of human subjects
• Participant interviews 
• Specimen processing 
• Establishing blood bank and blood testing
• Data collection and analysis
• Writing project progress report
• Grant and budget  development

Clinical Research Assistant Professor

Internal Medicine, Wayne State University, Detroit, MI (04/04-04/12)

Early diagnosis of breast cancer study with the experiences in: 

• Design and planning of  the breast cancer research project 
• Supervising research associates and assistants
• Developing and modifying protocol
•  Quality Control
•  Writing progress reports 
• Training residents and postdoctoral       in clinical research
• Collecting data and performing       data analysis 
• Making and controlling the budget
• Patient specimen  collection
• Performing all the research work in the lab

Lab Manager and Research Associate, Clinical Pathology

William Beaumont Hospital, Royal Oak, MI. (1996-1999)

•  Development and modification of molecular protocols of MPO test for clinical diagnosis of leukemia. 

Lab Manager and Research Associate

• Molecular Biology Laboratory, Cardiovascular Institute, Beijing Medical University, Beijing, China (09/90- 07/93)
• Design and plan the research project
• Develop and modify protocols
• Supervise research associates and assistants
• Quality Control
• Data analysis 
•  Write progress report 

Group Leader of Union

Department of Biochemistry, Dalian Medical University, Dalian, Liaoning, P.R. China, (09/88-07/90)

Assistant of Chair

Department of Biochemistry, Dalian Medical University, Dalian, Liaoning, P.R. China, (09/86-07/90)

•  Assist Chair in making teaching and medical research plans 
•  Collaborate and communicate with other departments 
• Write the annual report 

FUNDINGS 

National Cancer Institute SBIR Contract Phase 2 (HHSN261201200043C)

N. Tang, CO-PI

“Photonic Crystal Microarray nano-platform for high throughput highly sensitive and highly specific detection and identification of cancers” $1,000,000 (5% Effort), 9/30/2012-09/30/2014

 US Army ECBC SBIR Contract (W911SR-12-C-0046)

N. Tang, CO-PI 

“Monolithic photonic crystal on-chip absorption spectrometer for laser absorption spectroscopy” Phase 2, 

$780,000 (5% Effort) 05/03/2012-05/02/2014

NIH/ NIEHS Grant, Phase 2 (9R42ES024023)

N. Tang, CO-PI

“Resonant-Photonic-Device-Enhanced SERS Substrates with Pinpointed Plasmonic-Active Nanotubes for Ultrasensitive Biomolecule Detection” 

$1,000,000 (5% Effort), 09/15/2013-08/30/2015

Breath of Life foundation, NCVAC #026-129

N. Tang, PI

“New biomarkers discovery and the molecular mechanisms of carcinogenesis for Mesothelioma among Asbestos exposed Populations”

$200,000, 2010-2012.

 NIH-RO1.CA122277

N. Tang Co-investigator. F. Fernández Madrid PI.

“Development and validation of an autoantigen panel for the diagnosis of

breast cancer”

$ 1,670,000, 9/2008-8/2011

U.S. Environmental Protection Agency （2006-057）

N Tang, sub project PI

National Center for Vermiculite and Asbestos-related Cancers---

“Early Detection Biomarkers for Mesothelioma among Asbestos and

Vermiculite exposed Populations," 

$1,000,000, 3/2006-2/2010

 NIH: R21 AR-99-128 (CA-87759-02)

Tang N, Co-Investigator. F. Fernández-Madrid, PI.

  “Autoantibody to Nuclear Antigens as Markers of Breast Cancer”

  $223,500, 03/2001 – 02/2003

COLLABRATION WITH CHINA

 1.Zhongshan Hospital, Dalian University, Dalian, Liaoning, P.R. China (2012)

Early diagnosis for breast Cancer

       2. Tianjin Tumor Hospital, Tianjin, P.R. China (2010)

Early diagnosis for breast cancer 

  3. Shandong Medical Institute, Jinan, Shandong, P.R. China (2001) 

Cancer Drug development and animal study

SELLECTED PUBLICATIONS

• Hai Yan, Chun-Ju Yang,Naimei Tang, [...], Ray T Chen, “Specific Detection of      Antibiotics by Silicon On-chip Photonic Crystal Biosensor Arrays,” Aug 2017
• Lijun Huang, Hai Yan, Xiaochuan Xu, Swapanajit Chakravarty, Naimei Tang, Huiping Tian, and Ray      Chen, “Improving the detection limit for on-chip photonic sensor based on      subwavelength grating racetrack resonators,” Optics Express, Vol.25, No.9,      pp.10527- 10535, 2017.
• Swapnajit Chakravarty, Xiangning Chen, Naimei Tang… Ray Chen, “Review of      design principles of 2D photonic crystal microcavity biosensors in silicon      and their applications,” Frontiers of Optoelectronics 9(2):206-224, June      2016 
• Hai Yan, Naimei      Tang, Grace A. Jairo, [...], Ray T Chen, ”High-sensitivity      high-throughput chip based biosensor array for multiplexed detection of      heavy metals. Conference Paper, Mar 2016
• Hai Yan, Lijun Huang, Xiaochuan Xu, Swapnajit Chakravarty, Naimei Tang, Huiping Tian, and Ray      T. Chen, "Unique surface sensing property and enhanced sensitivity in      microring resonator biosensors based on subwavelength grating      waveguides," Opt. Express 24, 29724-29733 (2016).
• H. Yan, Y. Zou, S. Chakravarty, C.-J. Yang, Z. Wang, N. Tang, D. Fan and R. T. Chen.,      "Silicon on-chip bandpass filters for the multiplexing of high      sensitivity photonic crystal microcavity biosensors," Applied Physics      Letters, vol. 106, p. 121103, 2015.
• Chun-Ju Yang, Naimei Tang, Hai Yan[...], Ray Chen. 193nm Lithography      Fabricated High Sensitivity Photonic Crystal Microcavity Biosensors for      Plasma Protein Detection in Patients with Pancreatic Cancer. CLEO, OSA      Technical Digest (online) Optical Society of America, May 2015. 
• Xinbo      Zhang*, Naimei Tang*,      Crystal S Zhang, Shihong Mao, Anil Wali, Harvey Pass, Felix      Fernandez-Madrid, Michael R Harbut and Ann G Schwartz. Counterintuitive      features of side population cells in mesothelioma. Submitted to BMC      Cancer, December 2012
• Crystal      Siyu Zhang1, Xinbo Zhang2, Felix Fernandez-Madrid2,      Harvey Pass3, Ann Swartz2, 4, Michael Harbut5,  Naimei      Tang2,5, Identification of an autoantibody panel      as a potential signature of malignant pleural mesothelioma. 11th      International Conference of the International Mesothelioma Interest Group      (iMig 2012), Oral presentation, Boston, September 11 – 14, 2012
• Zhang X, Zhang SC, Sun D, Hu J, Wali A, Pass      H, Fernandez-Madrid F, Harbut MR, Tang      N*. New insight into the molecular mechanisms of the biological      effects of DNA minor groove binders. PLoS ONE. 6(10):e25822 2011.
• Zhang X, Tang      N, Hadden TJ, Rishi A. Akt, FoxO and regulation of apoptosis. Biochim      Biophys Acta. 1813:1978-1986, 2011.
• Tang N, Zhang X, Pass H, Wali A, Madrid F,      Schwart A, and Harbut M. Differential gene expression profiles of side      population cells from Mesothelioma cell lines. 2010 ASCO- NCI – EORTC      Annual Meeting on Molecular Markers in Cancer. Hollywood, Florida, October 18 -20,      2010. 
• Madrid      F*, Chen W, Tang N, Zhang X, Dong J, Sagar H and Abrams J. Autoantibodies in Breast Cancer      Identify Proteins Involved in Self-Renewal and Epigenetic Chromatin Remodeling.      The Open Biomarkers Journal, 3, 1-8, 2010
• Pass      HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M,      Allard J. Soluble mesothelin-related peptide level elevation in      mesothelioma serum and pleural effusions. Ann Thorac Surg. 85(1):265-72;      discussion 272, 2008.
• Harvey I. Pass, Dan Lott, Fulvio Lonardo MD,      Michael Harbut , Zhangdong Liu , Naimei Tang PhD*, Michele Carbone,      Craig Webb, and Anil Wali. Asbestos Exposure, Pleural Mesothelioma, and      Serum Osteopontin Levels. NEJM 353:1564-73, 2005.
• Fernandez Madrid F, Karvonen RL, Ensley J,      Kraut M, Granda JL, Alansari H, Tang N, Tomkiel JE. Spectra of      antinuclear antibodies in patients with squamous cell carcinoma of the      lung and of the head and neck. Cancer Detect Prev. 29: 59-65, 2005.
• Fernandez Madrid F, Tang N, Alansari H,      Karvonen RL, Tomkiel JE. Improved approach to identify cancer-associated      autoantigens. Autoimmun Rev. 4: 230-5, 2004.
• Fernandez-Madrid F, Tang N, Alansari H,      Granda JL, Tait L, Amirikia KC, Moroianu M, Wang X, Karvonen RL.      Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of      Breast Cancer. Cancer Res, 64:5089-96, 2004.
• Tomkiel      JE, Alansari H, Tang N, Virgin JB, Yang X, VandeVord P, Karvonen      RL, Granda JL, Kraut MJ, Ensley JF, Fernandez-Madrid F. Autoimmunity to      the M(r) 32,000 subunit of replication protein A in breast cancer. Clin      Cancer Res. 8: 752-8, 2002.
• ZC Cui,      KL Ma, XB Zhang, and NM Tang. Effects of Ganglioside GM3 on
• Phospholipid      Turnover of Human Leukemic J6-2 Cells. Neurochemical Research, 27: 771-778,      2002.
• Seyfried      DM, Veyna R, Han Y, Li K, Tang, NM, Betts RL, Weinsheimer S, Chopp      M, Anagli J. A selective cysteine protease inhibitor is non-toxic and      erebroprotective in rats undergoing transient middle cerebral artery      ischemia. Brain Res. 901: 94-101, 2001.
• Tang      NM, Dong HW, Wang XM,      Tsui ZC, Han JS. Cholecystokinin antisense RNA increases the analgesic      effect induced by electro-acupuncture or low dose morphine: conversion of      low responder rats into high responders. Pain, 78:71-80, 1997.
• Tang      NM, Dong HW, Wang XM,      Tsui ZC, Han JS. CCK antisense RNA could reverse nonresponder to responder      on 100Hz electroacupuncture analgesia. Chinese J. of Pain. 1: 45-48, 1996.      (Chinese).
• XB      Zhang, NM Tang, Q Xia, ZM Zhu, ZC Tsui. Effect of differentiation      inducers on the lectin binding capacity of a human monocytoid J6-2      leukemic cells and on the incorporation of [125I] UdR into the cells.      Chinese J Pathophysiol, 11: 582-586, 1995 (Chinese).
• NM      Tang, XM Wang, JS Han.      A simple and efficient method for preparation of plasmid DNA. Life      Chemistry, 8: 35. 1995. (Chinese).
• NM      Tang, HW Dong, XM      Wang, ZC Tsui, JS Han. Effect of CCK sense and antisense RNA on low-lose      morphine analgesia of rats. Chin Sci Bul, 11: 156-158, 1994. (Chinese).
• NM      Tang, SY Sun, BB Ke, J      Tang. Expression of TGF-2 gene in cardiovascular
• diseases.      Chin Biochem J, 10: 30-33, 1994.(Chinese).
• NM      Tang, XB Zhang, ZM      Zhu, ZC Cui. Studies on glycosphingolipid changes in carbon tetrachlorideintoxicated      rat liver. Chin J Ind Hyg Occup Dis, 12: 269-271, 1994;(Chinese).
• NM      Tang, YDYong, BB Ke, J      Tang. Expression of vascular endothelial growth factor in atherosclerotic      plaques of rabbits. J of Beijing Medical University, 106: 471-473, 1993. (Chinese).

• Strong innovation and creativity
• Key person in several projects and assignments
• Over 30 years of proposal writing and grant application experience
•  Master cutting edge techniques such as NGS, autoantigen panel study, transgenic study along with the skills of molecular biology, cell biology, lipid study, and animal study 
• Strong molecular biology, cell biology, microbiology, biochemistry, and biomedical background and over 30 years of experience in the field of biomedical research
• 
  

CHM BioHealth LLC, Austin, TX 78750                                                             2018-Current

 CTO

Design and develop panels of cancer-associated antigens for early diagnosis of cancers

   CHM Adult Care Center, Round Rock, TX 78681 2013-2018

•  Participate in application for a license from Texas Department of Aging and Disability Services
• Consultation of medical knowledge

Asuragen, Austin, TX 78744

• Develop two magnetic beads normalizing protocol to normalize gene specific libraries for MiSeq run
•  Use next generation sequencing to detect gene mutations in cancer patient samples

Internal Medicine, Wayne State University, Detroit, MI 48201 2009-2013

• Develop and validate an autoantigen panel for the diagnosis of breast cancer and malignant pleural mesothelioma.
• Identify an auto-antibody panel of side population cells to mesothelioma early diagnosis and relapse surveillance
•  Identify key genes for targeted-cancer stem cell therapy of malignant pleural mesothelioma after DNA minor groove binder-induced apoptosis
• Study the effect of DNA minor groove binder, Hoechst 33342 on tumorigenesis of breast cancer cell lines in the nude mice

Pulmonary Dept, Detroit VA Hospital, Detroit, MI 48201 2006-2008

• Study the biological and molecular responses of malignant plural mesothelioma cells to tyrosine kinase inhibitor treatments, and its mechanisms
• Study the role of DNA methylation in gene expression regulation of malignant plural mesothelioma

Clinical Pathology, William Beaumont Hospital, Royal Oak, MI 48073 1996-2005

•  Study DNA minor groove binder-induced apoptosis and its mechanisms
• Transcription factors as potential targets of minor groove DNA binder for targeted cancer therapy
•  Study auto-antibodies as biomarker panel for diagnosis of immune cholangiopathies
• Develop a BCR-ABL gene PCR method to diagnose chronic myeloid leukemia
• Screen efficacy of antivirus drugs using dengue virus

Hypertension, Henry Ford Hospital, Detroit, MI 48202 1994-1995

•  Study ischemia-induced apoptosis and gene expression in the infarcted myocardium of rats
•  Establish hBNP promoter-driven luciferase or kallikrein transgenic mice

Cardiopulmonary Institute, Beijing Medical University, Beijing 1992-1994

• Study hypertension-induced gene expression 
•  Study NO-associated gene expression in hypertensive animals 

• M.D. Inner Mongolia Medical College, Huhehaote, P.R. China, 1979-1984
• M.S. Henan Medical University, Henan, P.R China, 1984-1987
• Ph.D. Biochemistry, Dalian Medical College, Dalian, P.R. China, 1987-1990
•  Postdoc Fellowship. Physiology, Beijing Medical University, Beijing, P.R. China, 1990-1992
•  Certified by Educational Commission for Foreign Medical Graduates, USA, 2006

•  Key writer and designer for many grants including NIH and DOD grants, and internal grant
• Zhang X, PI, “Effect of DNA minor groove binder, Hoechst 33342 on tumorigenesis of breast cancer cell lines in the nude mice”. Wayne State University, IACUC Number: A08-10-12, 2012

• Rishi AK, Zhang X, Wali A. Targeting of apoptosis signaling pathways and their medicine. In Pharmaceutical Perspectives of Cancer Therapeutics edited by Lu Y, Mahato RI (Springer), pp.149-188. 2009
• Zhang X, Kiechle FL. Electrophoretic mobility shift assay: a useful technique for detecting DNA-binding proteins. Molecular Diagnostics and Immunopathology Check Sample 5:15-31, 2001. No. MDI01-2. Am Soc Clin Pathol: Chicago, IL

• Zhang X, Tang N, Rishi AK, Pass HI, Wali A. Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options. Methods Mol Biol.1238:235-47, 2015
• Zhang X, Zhang SC, Sun D, Hu J, Wali A, Pass H, Fernandez-Madrid F, Harbut MR, Tang N. New insight into the molecular mechanisms of the biological effects of DNA minor groove binders. PLoS ONE. 6:e25822, 2011
•  Zhang X, Tang N, Hadden TJ, Rishi A. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 1813:1978-1986, 2011
• Madrid F, Chen W, Tang N, Zhang X, Dong J, Sagar H and Abrams J. Autoantibodies in Breast Cancer Identify Proteins Involved in Self-Renewal and Epigenetic Chromatin Remodeling. The Open Biomarkers J. 3:1-8, 2010.
•  Kiechle FL, Zhang X, Holland C. Molecular pathology: future issues. Arch Pathol Lab Med. 30:650-653, 2006
• Zhang X, Kiechle FL. Fatty acid synthase and its mRNA concentrations are decreased at different times following Hoechst 33342-induced apoptosis in BC3H-1 myocytes. Ann Clin Lab Sci. 36:185-193, 2006
• · Chen JC, Zhang X, Singleton TP, Kiechle FL. Mitochondrial membrane potential change induced by Hoechst 33342 in myelogenous leukemia cell line HL-60. Ann Clin Lab Sci. 34:458- 466, 2004
• Zhang X, Kiechle FL. Cytosine arabinoside substitution decreases transcription factor/DNA binding element complex formation. Arch Pathol Lab Med. 128:1364-1371, 2004
• Kiechle FL, Zhang X, Holland-Staley CA. The –omics Era and its impact. Arch Pathol Lab Med. 128; 1337-1345, 2004
•  Zhang X, Kiechle FL. Review: Glycosphingolipids in health and disease. Ann Clin Lab Sci. 34:3- 13, 2004
•  Zhang X, Kiechle FL. Hoechst 33342 alters leuciferase gene expression in transfected BC3H-1 myocytes. Arch Pathol Lab Med.127:1124-1131, 2003
• Kiechle FL, Zhang X. Apoptosis: biochemical aspects and clinical implications. Clin Chim Acta. 326:27-45, 2002
• Cui ZC, Ma KL, Zhang X, Tang NM. Effects of Ganglioside GM3 on Phospholipid Turnover of Human Leukemic J6-2 Cells. Neurochemical Research. 27:771-778, 2002
• · Zhang X, Kiechle FL. Hoechst 33342-induced apoptosis is associated with an accumulation of E2F-1 protein in BC3H-1 myocytes and HL-60 cells. Arch Pathol Lab Med. 125:99-104, 2001
• Zhang X, Kiechle FL. Hoechst 33342-induced apoptosis is associated with decreased immunoreactive topoisomerase 1 and topoisomerase 1-DNA complex formation. Ann Clin Lab Sci. 31:187-198, 2001
• Zhang X, Kiechle FL. Disruption of replication protein A/single-stranded DNA complxes during apoptosis in HL-60 cells. Biochem Biophys Res Commun. 287:865-869, 2001
• Kiechle FL, Zhang X. In reply: Hoechst 33342-induced apoptosis. Arch Pathol Lab Med.124: 804-805, 2000
• Kiechle FL, Zhang X, Malinski T. The molecular pathology laboratory of the 21st century. Ann Clin Lab Sci. 29:59-77,1999
• Zhang X, Chen J, Davis BH, Kiechle FL. Hoechst 33342 induces apoptosis and inhibits topoisomerase I in vivo in human leukemic HL-60 cells. Arch Pathol Lab Med. 123:921- 927,1999
• Zhang X, Kiechle FL. Mechanism of Hoechst 33342-induced apoptosis inBC3H-1 myocytes. Ann Clin Lab Sci.28:104-114, 1998
•  Zhang X, Kiechle FL. Hoechst 33342 induces apoptosis and alters TATA box binding protein
• /DNA complexes in nuclei from BC3H-1 myocytes. Biochem Biophys Res Commun. 248:18- 21,1998
• Zhang X, Kiechle FL. Hoechst 33342-induced apoptosis in BC3H-1 myocytes. Ann Clin Lab Sci. 27:260-275,1997
• Zhang X, Tang NM, Zhang XJ. Effect of Ganglioside GM3 and phospholipid composition of rate hepatocytes. Chinese Science bulletin. 38:1918-1921, 1993.
• Zhang X, Tang NM. A method for micro-scale ganglioside purification. Acta Biochim Biophys Sinica. 25:187-190, 1993.
• · Zhang X, Cui ZC, Tang N, Zhu ZM. The differentiation of J6-2 cells induced by ganglioside GM3 and the comparison of glycosphingolipid and phospholipid composition before and after differentiation. Prog Biochem Biophys. 19:123-127,1992.
• Cui ZC, Zhang X, Tang NM, Zhu ZM. Effect of a cell differentiation inducer ganglioside GM3 on the phospholipid metabolism of a human monocytoid leukemia J6-2 cells. Chinese Biochem. J. 8:724-729, 1992.

· Not listed

•  国家中医糖尿病学科带头人，“泰铭手针”创始人，中国首届百名杰出青年中医，现任山西广济中医糖尿病防治研究所所长，山西广济医院院长，中华中医药学会理事，中华中医药学会糖尿病分会副主任委员，中华中医药学会中国名医学术思想研究会理事，中华中医药学会中医学术流派学会副主任委员，北京大学中文核心期刊评审专家，美国中华医学会客座教授，美国科学促进会会员，美国国际糖尿病研治中心主任，世界针灸学会联合会会员，罗马尼亚针灸协会荣誉会员，中国文化研究会传统医学专业委员会全国委员，人事部中国人才科学研究院人事与人才科学研究所教授，农工民主党山西省委委员，山西省第八、九届政协委员。
• 张教授是有着650多年行医历史的中医世家第21代传人，自幼随父学医，致力于医学的研究，钻研中医理论，注重实践，博采众长，擅长治疗疑难杂症、妇科病。他受恩师“济慈神针”（“药王”孙思邈的传人）传授，在此基础上创立了“泰铭手针疗法”，治疗急慢性疾病，进针得气即刻显效，如肩周炎、半身不遂、腰痛、头痛等多年不愈疾病，有的患者针一至三次而愈，曾获山西省针灸大赛一等奖。  
•  张教授曾先后随卫生部出访马来西亚、印度尼西亚、巴基斯坦、美国、欧洲等国进行学术交流，并多次运用针灸及中医药治好多国元首及官员的顽疾，他精湛的针灸技术使国外医学界的同仁们惊叹不已，蜚声海内外。 
•  张教授从脏腑、经络入手，精研古典中医药学名著，结合现代医学的研究成果，在大量治疗糖尿病临床实践的基础上不断探索总结。
  
  　　1990年首创了防治糖尿病的“多维全息综合疗法”，通过山西省科学技术委员会组织的专家鉴定，经省科委情报研究所全球检索，属世界首创。
  
  　　1992年获山西省科学技术进步二等奖。并创办了集科、医、工、贸、慈善为一体的中国首家糖尿病研究所——山西广济中医糖尿病防治研究所。1993年，研究所被认定为国家级太原高新技术产业开发区企业。
  
  　　1994年初，为弘扬祖国传统医学之精华，正确引导我国中医专科的发展方向，为有才华的专科疾病治疗专家提供施展才能的机会，给广大患者提供真实、权威的就医场所。在中国卫生部各级领导的支持下，国家中医药管理局和相关部门在全国范围内开始了对中医专科、专病治疗的为期两年的核查与验证工作，并在北京筹备建立“全国专科疾病北京中医药治疗中心”。 1996年5月，由国家卫生部、北京市卫生局、国家中医药管理局批准，“全国专科疾病北京中医药治疗中心”正式成立。该中心共有十大科室，每个科室均由一位中医专家负责。这十位专家都是从全国各省（市）卫生部门推荐的中医专家名单中选出，在广泛听取患者意见的基础上，经过多位专家反复验证、评比，最终择优筛选出的疗法独特、疗效确切的优秀医学专家。张泽全非常荣幸地在全国七十多位中医糖尿病专家中脱颖而出，成为唯一中选进京的糖尿病主治专家。作为中国中医治疗各种疑难疾病的专科权威机构，中心的工作得到了卫生部等有关主管单位及各级领导的大力支持。原卫生部长陈敏章、崔月犁、张文康等都多次来中心视察，并参观了张泽全所在的糖尿病科室。他们亲眼见识了张泽全医生平易近人的风范以及他运用精湛的医术和科学的疗法为世界各地慕名而来的糖尿病患者解除痛苦的感人场景，纷纷对其工作成绩表示肯定并题词留念。现任国家中医药管理局佘靖局长与有关领导也多次莅临，对科室的医疗工作也给予了高度评价。新华社、《人民日报》、《法制日报》、《经济日报》、《北京日报》、《健康报》等二十多家新闻单位和报纸都报道了张泽全的事迹及其研究成果。中央电视台、北京电视台等多家媒体对此均进行过深入报导。
  
  　　1997年建立了中国第一家糖尿病专科医院——山西广济医院。
  
  　　2001年研制的治疗糖尿病新药——糖消胶囊（后改名为“参地益阴胶囊”），获中国发明专利。荣获首届国际爱因斯坦新发明、新技术博览会国际新产品金奖。
  
  　　2002年，张泽全教授任职美国国际糖尿病研治中心主任，与美国医学科学专家研究糖尿病的防治，研制出防治糖尿病和亚健康的高科技“益康系列”产品，益康系列产品以高质量的品质 。

•  2002年11月1日，张泽全教授研发的“参地益阴胶囊”被国家药监局批准为国家新药（是从第二次世界大战以来全球范围内屈指可数的真正的“新药”）。2004年获中华人民共和国知识产权局发明专利，专利号ZL01102942。
  
  　　多年来，张泽全教授研究出治疗糖尿病的数十种中药剂型和与此相关的保健品，并在国内外发表了很多学术论文。2005年～2010年，以他独有的知识产权和专利，研究所及他个人年年都获得太原国家高新技术产业开发区颁发的优秀自主创新奖、优秀专家奖、自主创新示范企业奖、太原市优秀企业家等奖项。
  
  　　2008年5月受罗马尼亚中医学会和罗马尼亚针灸学会邀请作为首席VIP赴欧洲讲学。
  
  　　2008年8月，张泽全出版了两部著作《糖尿病治疗新概念》、《【孙子兵法】与疑难疾病的治疗》。其中，《【孙子兵法】与疑难疾病的治疗》一书前后耗时10余年之久方才出版，是中国历史上第一部把《孙子兵法》的思想运用到医学方面并进行系统论述的书籍。
  
  　　2009年8月举办了首届国际手针研修班，吸引了欧洲很多著名的优秀医生前来参加培训和学习。
  
  　　2009年11月下属的糖尿病专科医院——山西广济医院被中华中医药学会评为国内唯一的“全国中医药防治糖尿病临床技术继续教育基地”。旨在通过在全国范围内培训专业中医技术人才，将山西广济医院运用中医药防治糖尿病方面优秀的经验、临床技术知识在全国推广、传播；为更多的中医学员掌握好防治糖尿病的专业知识提供了良好的平台，为我国发展中医药建设队伍产生了重要意义；更为改善糖尿病患者的生存状态，造福更多的患者，搭建出一条充满希望的“健康之路”！此次，山西广济医院在全国多家著名的三甲医院共同竞争的情况下脱颖而出，凭借张泽全教授及其领导下的山西广济医院在世界糖尿病治疗领域的综合实力与影响力，当之无愧的获得这一殊荣。这不仅是张泽全教授的骄傲，更是“泽全广济”人与山西广济医院的骄傲……
  
  　　2009年11月，张泽全教授受世界针灸学会和世界卫生组织邀请，以首席VIP身份出席在法国斯特拉斯堡欧洲议会大厦举办的第七届世界针灸学术大会，并作为大会上第一位发言的中国专家为到场的来自39个国家和地区的500多名世界各国的针灸学术团体和代表讲授他独创的手针疗法。
  
  　　2011年1月1日，张泽全教授新书《泰铭手针》在全国各大新华书店上架。《泰铭手针》一书的出版目的就是让更多的人了解学习，更好的发挥中医治病救人的作用。本书对于急症抢救、慢性病治疗、战地救护以及疼痛治疗，疗效显著，且应用方便，疗效快速，费用低廉，更好的做到广施良药，治病救人。 。。。。。

•  袁红霞教授，医学博士，天津中医药大学教授，博士生导师，首批全国优秀中医临床人才，第七批全国老中医药专家学术经验继承工作指导老师，天津市名中医（网址www.yhxtcm.com），英国曼彻斯特大学医学院高级访问学者，中华中医药学会脾胃病分会副主任委员，天津市中医药学会消化疾病专业委员会名誉主任委员。
• 从事中医药临床、教学及科研工作30余年，临证善用“经方”，在全国占据重要学术地位。主持30余项国家及省部级科研课题（主持5项国自然），发表学术论文300余篇，学术论著10余部，培养博硕士研究生160余名。
• 《经方应用与医案解读》系列课经方是医圣张仲景千年垂范的经典名方，是中医学的精华所在，经方体现了中医“简便廉验”，经方使用并不追求无比深奥的道理，“仲景之道，至平至易，仲景之门，人人可入。” 古往今来,善用经方、活用经方的中医名家不乏其人，经方的学习研究千百年间绵延不绝，也深刻影响了日本汉方为代表的海外中医发展。袁红霞教授在30余年临床工作中一直提倡“读经典、做临床、用经方”，并躬身践行，以善用经方蜚声医林，疗效卓著。
• rofessor Yuan Hongxia is a Doctor of Medicine, a professor at Tianjin University of Traditional Chinese Medicine, a doctoral supervisor, one of the first batch of excellent Chinese medicine clinical talents nationwide, a guiding mentor of the seventh batch of national traditional Chinese medicine expert academic experience inheritance work, a renowned Traditional Chinese Medicine practitioner in Tianjin (Website www.yhxtcm.com), a senior visiting scholar at the University of Manchester Medical School in the UK, vice-chairman of the Spleen and Stomach Diseases Branch of the Chinese Traditional Medicine Association, and honorary chairman of the Digestive Diseases Professional Committee of the Tianjin Traditional Chinese Medicine Association. She has been engaged in the clinical practice, teaching, and research of traditional Chinese medicine for over 30 years, skillfully using the "Classical Prescriptions," and holds a significant academic position nationwide. She has presided over more than 30 national and provincial-level scientific research projects (including 5 from the National Natural Science Foundation), published over 300 academic papers, authored over 10 academic books, and mentored over 160 master's and doctoral students.

• 张军教授，男，毕业于北京中医药大学，深圳市中医院骨科主任医师，硕士，留德学者，哈佛大学医学院校友。

现任: 

• 中华中医药学会外治分会全国常委，
• 中国民族医药学会微创技术分会副会长
• 深圳市汉章针刀医学会会长
• 深圳市中西医结合学会疼痛专业委员会副主任委员，
• 深圳市康复医学会骨科康复专业委员会副主任委员，
• 深圳市老年病学会副会长等。

      擅长：

•  1.骨伤科：顽固性颈椎病﹑肩周炎﹑腰椎间盘突出症﹑膝骨关节炎、腰椎滑脱症；青少年脊柱侧弯；骨质增生、骨质疏松、运动损伤、急慢性软组织损伤、股骨头坏死；骨伤康复；痛风、强直性脊柱炎﹑类风湿关节炎、风湿痹痛等风湿免疫疾病。
•  2.神经系统：头痛﹑眩晕﹑失眠，偏瘫、面瘫等。
•  3.健康管理，养生、治未病、提高免疫力，戒烟综合征，产后康复，男性功能障碍，美容美体塑形等。
•  综合治疗效果比较显著，使众多重症患者免除了手术之苦，患者慕名从美国、泰国、哈萨克斯坦等国及国内各省市而来，多次上报纸、电视，被选拔为部分中央领导同志、来访国宾、市领导等进行中医保健治疗，被邀请在北戴河及邻国总统府诊疗。

• Pingrong graduated from NanJing University of Chinese Medicine with a bachelor’ degree in acupuncture and Tuina, and studied Oriental medicine and acupuncture at California Alhambra Medical University and obtained a master’ degree.more than 15 years of clinical experience,specializing in pain symptoms, using the external methods of Traditional Chinese Medicine in clinic. Now running NEW SUNSHINE MEDICAL CENTER and JOYEE ACUPUNCTURE.
•  美國 加州執照針灸師,南京中醫藥大學針灸推拿學士,美國仁愛醫科大學東方醫學碩士,15年專于痛症，擅長運用中醫外治法，治療頸椎病，肩周炎，腰腿痛及各種痛症。現經營美國新陽光醫療中心JOYEEACUPUNCTURE 中醫針灸師。

• Danny attended the Alhambra Medical University for his Medical Degree and completed her residency in Tianjin University of Traditional Chinese Medicine .Born in a family of Chinese medicine practitioners, he is familiar with Chinese and Western Chinese medicine culture and education. He has graduated from major universities in the United States and China and has published excellent papers. Organized multi-disciplinary international Chinese medicine seminars.   Now running TAI-MING ACUPUNCTURE CLINIC in Arcadia, Californian. 
• 加州執照針灸師，天津中醫藥大學針灸推拿學博士，擅長于治療各種疼痛性疾病，中風後遺症和糖尿病並發症。現經營泰銘中醫堂，位于美國加州亚凯迪亚市.